Enosis Therapeutics, a medical technology and psychedelic research company that leverages virtual reality (VR) for the contextual modulation of psychedelic therapy to improve treatment outcomes, has partnered with OVID Clinics and the MIND Foundation to implement the world’s first in-clinic application of VR with Psychedelic-Assisted therapy. The Berlin-based healthcare services provider that delivers integration-focused and psychedelic-based psychotherapies through its network of clinics, “OVID Clinics”, has begun offering its patients the opportunity to receive psychedelic-assisted psychotherapy integrated with Enosis’ science-backed virtual technology protocols.
Also Read: PayBito Offers Crypto Payment Gateway Solutions to an Australian Financial Institution
In June 2022, Enosis collaborated with the Swinburne University of Technology in Australia and announced positive results from the world’s first study on the synergistic application of VR in psychedelics. The preliminary results showed that Enosis’ bespoke VR scenarios, combined with a guided psychedelic experience, generated high levels of acceptance and satisfaction. The positive results from this first study have led Enosis’ to begin offering VR scenarios with psychedelic-assisted therapy inside OVID Clinics.
“The Enosis team is honored to partner with OVID Clinics and the MIND Foundation to commence the first in-clinic application of our VR protocols as an adjunct to psychedelic-assisted psychotherapy,” said Agnieszka D. Sekula, Co-Founder of Enosis Therapeutics. “Enhancing patient accessibility to our VR experiences remains our top priority and we are excited to bring this novel treatment to patients in need. Together with the OVID team, our focus is to achieve positive patient outcomes and longer-lasting therapeutic benefits for patients battling mental health illnesses.”
Beyond offering the in-clinic protocol in Berlin, Enosis and OVID will be gathering data for a research collaboration aiming to investigate the synergistic effects of psychedelic and digital interventions in hopes that the results demonstrate better therapeutic patient outcomes and enhance overall patient wellbeing.
“At OVID Clinics, we believe in a personalized, evidence-based, medical & psychotherapeutic approach tailored to the patients’ needs. We recognize the value of Enosis´ VR technologies in the integration process following psychedelic therapy,” said Sergio Pérez Rosal, Co-Founder and Chief Executive Officer of OVID Clinics. “We are convinced that this partnership will help innovate the field by shifting the focus from the psychedelic substance to the psychedelic experience and its integration, supporting patients in every step of the way through their journey into well-being.”